Addus HomeCare Corporation (ADUS)vsJohnson & Johnson (JNJ)
ADUS
Addus HomeCare Corporation
$96.89
-0.07%
HEALTHCARE · Cap: $1.81B
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 6674% more annual revenue ($96.36B vs $1.42B). JNJ leads profitability with a 21.8% profit margin vs 6.7%. ADUS appears more attractively valued with a PEG of 0.96. ADUS earns a higher WallStSmart Score of 70/100 (B).
ADUS
Strong Buy70
out of 100
Grade: B
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+25.9%
Fair Value
$152.11
Current Price
$96.89
$55.22 discount
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 52.1% YoY
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 25.6% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
6.7% margin — thin
Weak financial health signals
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ADUS
The strongest argument for ADUS centers on EPS Growth, Altman Z-Score, PEG Ratio. Revenue growth of 25.6% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : ADUS
The primary concerns for ADUS are Market Cap, Profit Margin, Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ADUS profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
ADUS carries more volatility with a beta of 0.96 — expect wider price swings.
ADUS is growing revenue faster at 25.6% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
ADUS scores higher overall (70/100 vs 59/100) and 25.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Addus HomeCare Corporation
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Addus HomeCare Corporation, provides personal care services to the elderly, the chronically ill, the disabled, and people who are at risk of hospitalization or institutionalization in the United States. The company is headquartered in Frisco, Texas.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?